Monday, December 31, 2018

Shilpa Medicare gets USFDA nod for cancer treatment injection

Shilpa Medicare gets USFDA nod for cancer treatment injection The company has received US Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL injection USP in the strengths 40 mg/2mL and 100 mg/5mL (20mg/mL) single dose vials, Shilpa Medicare said in a BSE filing.

from Moneycontrol Business News http://bit.ly/2QeZD2x
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

US stock: S&P 500 ends lower as investors weigh data, Middle East tensions

The S&P 500's streak came to an end, falling from its peak as weaker retail sales suggested caution among consumers. Despite a stron...